Drug Search Results

Voglibose

Alternative Names: voglibose, basen, ao-128
Latest Update: 2024-04-29
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: GAA Inhibitor,GH Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Voglibose

Countries in Clinic: China

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Hyperglycemia

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
CTR20211468	P1	Not yet recruiting	Hyperglycemia	None
CTR20210954	P1	Not yet recruiting	Hyperglycemia	None

Recent News Events

Date	Type	Title
04/29/2024	PubMed	Extremophiles in a changing world.
04/03/2024	PubMed	Real-World Assessment of Personalized Approach With Voglibose Fixed-Dose Combination in Type 2 Diabetes Mellitus.
04/02/2024	PubMed	The energy-converting hydrogenase Ech2 is important for the growth of the thermophilic acetogen Thermoanaerobacter kivui on ferredoxin-dependent substrates.
10/13/2023	News Article	Voglibose Tablets Market Size will Observe Lucrative Surge by the End 2029
04/05/2022	News Article	Voglibose Market by Type and Application - Share, Size, Growth, Opportunity and Forecast Till 2022-2031
03/31/2022	News Article	CBC Group-backed Hasten Biopharma successfully completes acquisition of five cardiovascular and metabolism drugs from Takeda
08/10/2021	News Article	Global EV Charging Cable Market Predicted to Garner Revenue of $1,277.7 million by 2026 at a CAGR of 31.5% from 2021-2026 - Exclusive Report [Pages-170] by Research Dive

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions